Pomalidomide approved for use across Europe
Pomalidomide (Pomalidomide Celgene®) has been granted a licence for use in myeloma patients across Europe. This decision by the European Commission follows the positive recommendation in May 2013 for pomalidomide by the Committee for Medicinal Products for Human Use (CHMP), within the European Medicines Agency (EMA).